NCT00575887

Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma

Efficacy of a Protracted Temozolomide Schedule in Patients With Progression After Standard Dose Temozolomide for High-grade Gliomas

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Marmara University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy of temozolomide on a protracted schedule, after standard 5-day temozolomide regimen in patients with recurrent or progressive high grade glioma.

Conditions

• Glioblastoma
• Astrocytoma
• Oligodendroglioma
• Brain Tumor, Recurrent

Interventions

Type	Name	Description
DRUG	Temozolomide	100 mg/m2/day, (PO) orally, on days between 1 and 21 of each 28 day cycles. Number of cycles: Until progression or unacceptable toxicity

Timeline

• Start date: 2006-08-01
• Primary completion: 2009-03-01
• Completion: 2009-03-01
• First posted: 2007-12-18
• Last updated: 2013-12-20
• Results posted: 2013-12-20

Locations

1 site across 1 country: Turkey (Türkiye)